Skip to main content
Top
Published in: Journal of Endocrinological Investigation 5/2018

01-05-2018 | Endocrinology & Art

Sir Jeffrey Hudson, the midget of the Queen Henrietta Marie

Authors: F. Trimarchi, F. De Luca

Published in: Journal of Endocrinological Investigation | Issue 5/2018

Login to get access

Excerpt

Henrietta Marie of France (1609–1669), Queen consort of England, Scotland, and Ireland as the wife of King Charles I, was portraited, for the first time by the great Flemish baroque artist Antoon van Dyk (Antwerp, 1599–London, 1641), when she aged 24 years (Fig. 1). The Queen is depicted together with her favorite court dwarf, 14 years old and tall less than 35.4 in. (circa 90 cm.), Jeffrey Hudson (1619–circa 1682). At the age of 30, Hudson reached his final height of 42 or 45 in. (106–114 cm). The phenotypical features of this boy (very severe growth retardation with normal body proportions, doll-like face, pre-pubertal aspect) give evidence to a possible diagnosis of congenital hypopituitarism, probably due to a genetic defect [1].
Literature
1.
go back to reference Arrigo T, Wasniewska M, De Luca F, Valenzise M, Lombardo F, Vivenza D, Vaccaro T, Coradi E, Biason-Lauber A (2006) Congenital adenohypophysis aplasia: clinical features and analysis of the transcriptional factors for embryonic pituitary development. J Endocrinol Investig 29:208–213CrossRef Arrigo T, Wasniewska M, De Luca F, Valenzise M, Lombardo F, Vivenza D, Vaccaro T, Coradi E, Biason-Lauber A (2006) Congenital adenohypophysis aplasia: clinical features and analysis of the transcriptional factors for embryonic pituitary development. J Endocrinol Investig 29:208–213CrossRef
2.
go back to reference Curtò L, Trimarchi F (2016) Hypopituitarism in the elderly: a narrative review on clinical management of hypothalamic-pituitary-gonadal, hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes dysfunction. J Endocrinol Investig 39:1115–1124CrossRef Curtò L, Trimarchi F (2016) Hypopituitarism in the elderly: a narrative review on clinical management of hypothalamic-pituitary-gonadal, hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes dysfunction. J Endocrinol Investig 39:1115–1124CrossRef
3.
go back to reference Cappa M, Iughetti L, Loche S, Maghnie M, Vottero A (2016) GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. J Endocrinol Investig 39:667–677CrossRef Cappa M, Iughetti L, Loche S, Maghnie M, Vottero A (2016) GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. J Endocrinol Investig 39:667–677CrossRef
4.
go back to reference Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P (2017) Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. J Endocrinol Investig 40:669–678CrossRef Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P (2017) Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. J Endocrinol Investig 40:669–678CrossRef
Metadata
Title
Sir Jeffrey Hudson, the midget of the Queen Henrietta Marie
Authors
F. Trimarchi
F. De Luca
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 5/2018
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0844-x

Other articles of this Issue 5/2018

Journal of Endocrinological Investigation 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine